1 Ocak 2018 Dergi makalesi Açık Erişim

Cetin, Aysun; Abdulrezzak, Ummuhan; Yilmaz, Semih; Zararsiz, Gokmen; Akkurt, Soner; Ucar, Mahmut; Kaynar, Leylagul; Yildizhan, Esra; Turak, Esra E.; Ozaslan, Ersin; Gundogan, Kursat; Inanc, Mevlude; Kula, Mustafa; Cetin, Mustafa

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/35731</identifier>
  <creators>
    <creator>
      <creatorName>Cetin, Aysun</creatorName>
      <givenName>Aysun</givenName>
      <familyName>Cetin</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Med Biochem, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Abdulrezzak, Ummuhan</creatorName>
      <givenName>Ummuhan</givenName>
      <familyName>Abdulrezzak</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Nucl Med, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yilmaz, Semih</creatorName>
      <givenName>Semih</givenName>
      <familyName>Yilmaz</familyName>
    </creator>
    <creator>
      <creatorName>Zararsiz, Gokmen</creatorName>
      <givenName>Gokmen</givenName>
      <familyName>Zararsiz</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Biostat, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Akkurt, Soner</creatorName>
      <givenName>Soner</givenName>
      <familyName>Akkurt</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Sports Med, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ucar, Mahmut</creatorName>
      <givenName>Mahmut</givenName>
      <familyName>Ucar</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Haematol &amp; Oncol, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kaynar, Leylagul</creatorName>
      <givenName>Leylagul</givenName>
      <familyName>Kaynar</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Haematol &amp; Oncol, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yildizhan, Esra</creatorName>
      <givenName>Esra</givenName>
      <familyName>Yildizhan</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Haematol &amp; Oncol, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Turak, Esra E.</creatorName>
      <givenName>Esra E.</givenName>
      <familyName>Turak</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Haematol &amp; Oncol, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ozaslan, Ersin</creatorName>
      <givenName>Ersin</givenName>
      <familyName>Ozaslan</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Haematol &amp; Oncol, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Gundogan, Kursat</creatorName>
      <givenName>Kursat</givenName>
      <familyName>Gundogan</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Internal Med, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Inanc, Mevlude</creatorName>
      <givenName>Mevlude</givenName>
      <familyName>Inanc</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Haematol &amp; Oncol, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kula, Mustafa</creatorName>
      <givenName>Mustafa</givenName>
      <familyName>Kula</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Nucl Med, Kayseri, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Cetin, Mustafa</creatorName>
      <givenName>Mustafa</givenName>
      <familyName>Cetin</familyName>
      <affiliation>Erciyes Univ, Fac Med, Dept Haematol &amp; Oncol, Kayseri, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>High Metabolic Tumor Volume And Total Lesion Glycolysis Derived From Baseline F-18-Fdg Pet/Ct May Predict The Metabolic Abnormalities In Newly Diagnosed Cancer Patients</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2018</publicationYear>
  <dates>
    <date dateType="Issued">2018-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/35731</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.4999/uhod.182445</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">The present study was conducted to investigate the role of total body Metabolic Tumor Volume (MTV, mm(3)) and Total Lesion Glycolysis (TLG) values obtained by PET/CT imaging for predicting metabolic abnormalities in newly diagnosed cancer patients. Patients having solid tumors with initial PET/CT staging were evaluated in a prospective cohort study. MTV and TLG values of all patients were measured besides SUV values as PET/CT parameters. Initial metabolic status of patients was evaluated based on basal metabolic rates, serum vitamin, mineral, and biochemical metabolite levels and antioxidant enzyme capacities. The MTV and TLG levels revealed significant relationships with cancer-induced metabolic abnormalities as high BMR and LDH, and low albumin levels as well as advanced stage and presence of metastasis (p&amp;lt;0.05). Cut-off values along with sensitivity and specificity rates in terms of high BMR (&amp;gt;20 Kcal/kg) were obtained to be &amp;gt; 52400 mm(3) for MTV (0.84 and 0.63) and &amp;gt; 274208 for TLG (0.84 and 0.63). The same values for high LDH were &amp;gt;= 219520 mm(3) (0.52 and 0.88) for MTV and &amp;gt;= 411792 (0.78 and 0.58) for TLG, respectively. The values for low albumin levels were &amp;gt;= 89520 mm(3) (0.63 and 0.10) for MTV, and &amp;gt;= 887840 (0.75 and 1.00) for TLG, respectively. In conclusion, MTV and TLG cut-off values determined by ROC analysis can predict metabolic abnormalities in initial BMR, LDH and albumin levels with high specificity and sensitivity. It is recommended to test MTV and TLG levels to determine initial metabolic status of diverse patient groups with various types of cancer.</description>
  </descriptions>
</resource>